Arthrolense Appoints Veteran MedTech Leader Oren Gelman as CEO to Advance the Next Era in Machine Vision Surgical Guidance

Audio By Carbonatix

TORONTO--(BUSINESS WIRE)--Sep 11, 2025--

Arthrolense, a medical technology innovator redefining visual surgical guidance in joint replacement, announced the appointment of Oren Gelman as President and Chief Executive Officer. Co-founders Dr. David Backstein and Dr. Russ Nevins will continue in leadership roles guiding clinical and strategic direction.

Merging medicine and technology, Arthrolense is transforming orthopedic care by integrating machine vision with machine learning for real-time data insights.

Arthrolense’s flagship 4DI visual guidance system was designed with patented camera technology and machine vision for real-time anatomy visualization, to provide surgeons with accurate intraoperative visualization, mapping, and tracking. By enabling dynamic assessment of joint anatomy at the point of care, the system is designed to enhance surgical decision-making, reduce variability, and support improved surgical outcomes.

With over 20 years of senior leadership experience in the medical device sector, Gelman brings a proven track record of scaling global businesses and driving adoption of advanced surgical technologies. He previously held leadership roles at DePuy Synthes, Ethicon, and Stryker Orthopaedics, leading large platforms, spearheading major product launches and portfolio expansions.

“Arthrolense is addressing significant unmet needs in orthopedics—equipping surgeons with accurate, real-time insights through machine vision and machine learning that are designed to enhance decision-making, increase personalization, and improve surgeon and patient satisfaction,” said Gelman. “I am honored to be working with the talented team at Arthrolense and its visionary co-founders to lead the company at this inflection point, advancing its technology toward commercialization for the benefit of patients and surgeons alike.”

The Arthrolense 4DI visual guidance system also incorporates unique capabilities to tackle high-priority clinical needs and aims to set a new standard with intelligent, machine vision enabled surgery.

Strategic Path Forward

Arthrolense has established a quality management system in line with global regulatory standards and is actively preparing for FDA submission. The company is also expanding its patent portfolio, advancing commercialization planning, and exploring partnerships to support market entry and scalability across the globe.

About Arthrolense

Arthrolense is transforming orthopedic surgery by merging machine vision and machine learning leveraging proprietary camera technology that delivers real-time intraoperative data and visualization. Arthrolense is developing a platform technology designed to deliver precision, personalization, and improved outcomes across a wide range of orthopedic indications.

Disclaimer: The Arthrolense device is not commercially available in the United States.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250909412378/en/

Media:[email protected]

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: RESEARCH TECHNOLOGY MEDICAL DEVICES SURGERY OTHER TECHNOLOGY HEALTH TECHNOLOGY GENERAL HEALTH HEALTH SCIENCE OTHER SCIENCE

SOURCE: Arthrolense

Copyright Business Wire 2025.

PUB: 09/11/2025 10:24 AM/DISC: 09/11/2025 10:23 AM

http://www.businesswire.com/news/home/20250909412378/en